These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38828460)

  • 21. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
    Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
    Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
    He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
    Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy.
    Tan L; Su X; Li X; Li H; Hu B
    Int J Clin Exp Pathol; 2020; 13(2):286-294. PubMed ID: 32211111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
    Ponde N; Bradbury I; Lambertini M; Ewer M; Campbell C; Ameels H; Zardavas D; Di Cosimo S; Baselga J; Huober J; Izquierdo M; Fumagalli D; Bozovic-Spasojevic I; Maetens M; Harbeck N; Pusztai L; Berghorn M; Im YH; Borrego MR; Chen DR; Rodeheffer R; Piccart M; Suter T; de Azambuja E
    Breast Cancer Res Treat; 2018 Apr; 168(3):631-638. PubMed ID: 29280043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer.
    Yang JX; Yang YQ; Hu WY; Yang L; Wu J; Wen XX; Yu J; Huang ML; Xu DD; Tie DC; Wang L; Li FF; Li NL
    Oncologist; 2024 Jan; 29(1):e15-e24. PubMed ID: 37279780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy.
    Li J; Zhang S; Ye C; Liu Q; Cheng Y; Ye J; Liu Y; Duan X; Xin L; Zhang H; Xu L
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
    Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab.
    Bouwer NI; Liesting C; Kofflard MJM; Sprangers-van Campen SM; Brugts JJ; Kitzen JJEM; Fouraux MA; Levin MD; Boersma E
    Cardiooncology; 2019; 5():4. PubMed ID: 32154011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
    Choi JH; Jeon CW; Kim YO; Jung S
    Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer-The EARLY-MYO-BC study.
    Chai Y; Jiang M; Wang Y; Liu Q; Lu Q; Tao Z; Wu Q; Yin W; Lu J; Pu J
    Front Cardiovasc Med; 2023; 10():1021937. PubMed ID: 36844736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
    Feng Y; Qin Z; Yang Z
    J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
    Zhou M; Wang S; Wan N; Yuan S; Hu X; Zhou W; Qing B; Liu M; Sun W; Fan P; Wang J; Cao H; Xu H; Dai B; Tang P; Qian L; Zhao X; Xiao J; Zhou H; Hu J; Ding L; Tripodi D; Zdenkowski N; O'Keefe TJ; Sanchez AM; Chen L; Zhang P; Xu F
    Ann Transl Med; 2022 Dec; 10(24):1387. PubMed ID: 36660637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of High-Sensitivity Cardiac Troponin I Values and Cardiac Radiation Doses in Patients with Left-Sided Breast Cancer Undergoing Hypofractionated Adjuvant Radiotherapy with Concurrent Anti-HER2 Therapy.
    Antunac K; Mayer L; Banovic M; Beketic-Oreskovic L
    Curr Oncol; 2023 Oct; 30(10):9049-9062. PubMed ID: 37887554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer.
    Qin X; Chang F; Wang Z; Jiang W
    Cancer Biomark; 2018; 23(4):473-484. PubMed ID: 30452398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.
    Peng DM; Li J; Qiu JX; Zhao L
    World J Surg Oncol; 2024 Apr; 22(1):88. PubMed ID: 38582875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial.
    Kirkham AA; Pituskin E; Thompson RB; Mackey JR; Koshman SL; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Tsui AK; Ezekowitz JA; Oudit GY; Paterson DI
    Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):130-139. PubMed ID: 33605416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.
    Ky B; Putt M; Sawaya H; French B; Januzzi JL; Sebag IA; Plana JC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    J Am Coll Cardiol; 2014 Mar; 63(8):809-16. PubMed ID: 24291281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.